Ischemic stroke prevention

被引:2
作者
Seemant Chaturvedi
Susan Hickenbottom
Steven R. Levine
机构
[1] Wayne State University School of Medicine,
[2] University of Michigan Medical Center,undefined
关键词
Warfarin; Clopidogrel; Dipyridamole; Ticlopidine; Stroke Prevention;
D O I
10.1007/s11940-999-0011-y
中图分类号
学科分类号
摘要
More than 700,000 strokes occur annually in the United States—one every 40 to 50 seconds. Although stroke is one of the nation’s most expensive diseases to treat, costing $41 billion per year, most strokes (perhaps as many as two thirds) are preventable. Twenty percent of the United States population will have 80% of all strokes; this estimate is based on five established, major risk factors for stroke: hypertension, diabetes mellitus, cigarette smoking, hyperlipidemia, and heart disease. Therefore, stroke is not random but is generally predictable. It is an ideal target for effective prevention strategies that are simple and inexpensive. Ischemic stroke prevention has been shown to be effective in several scenarios: primary prevention, prevention after a transient ischemic attack (TIA), and secondary prevention. Dietary, lifestyle, and risk factor modification; use of aspirin, ticlopidine, clopidogrel, and warfarin; and carotid endarterectomy all have a role in stroke prevention in selected persons. Emerging therapies include the use of vitamins, cerebral arterial angioplasty, and stenting. Annual risk assessment, screening, and intervention should be part of a concerted national effort to reduce the incidence of the third leading cause of death and the number one cause of adult disability in the United States.
引用
收藏
页码:113 / 125
页数:12
相关论文
共 50 条
  • [31] Anticoagulant Therapy in the Prevention and Treatment of Ischemic Stroke
    Bauer, Jiri
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2010, 73 (05) : 480 - 491
  • [32] Antiplatelet drugs in ischemic stroke prevention: From monotherapy to combined treatment
    Urbano, LA
    Bogousslavsky, J
    CEREBROVASCULAR DISEASES, 2004, 17 : 74 - 80
  • [33] Prevention of Stroke Following Transient Ischemic Attack
    Poisson, Sharon
    Johnston, S. Claiborne
    CURRENT ATHEROSCLEROSIS REPORTS, 2011, 13 (04) : 330 - 337
  • [34] The pharmacology of antiplatelet agents for primary, secondary, and tertiary prevention of ischemic stroke
    Laudani, Claudio
    Capodanno, Davide
    Angiolillo, Dominick J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (10) : 1373 - 1390
  • [35] Antiplatelet Agents for the Secondary Prevention of Ischemic Stroke or Transient Ischemic Attack: A Network Meta-Analysis
    Wang, Wen
    Zhang, Lu
    Liu, Weiming
    Zhu, Qin
    Lan, Qing
    Zhao, Jizong
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2016, 25 (05) : 1081 - 1089
  • [36] Antiplatelet treatment for secondary prevention of ischemic stroke or transient ischemic attack
    Barinagarrementeria, Fernando
    Arauz, Antonio
    Luis Ruiz-Sandoval, Jose
    Cantu, Carlos
    Leyva, Adolfo
    Murillo, Luis
    Villarreal, Jorge
    Dario Vargas, Ruben
    Antonio Alegria, Marco
    Merino, Jose G.
    Romano, Jose
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2010, 62 (02): : 135 - 140
  • [37] Triflusal and Aspirin in the Secondary Prevention of Atherothrombotic Ischemic Stroke: A Very Long-Term Follow-Up
    Alvarez-Sabin, Jose
    Quintana, Manuel
    Santamarina, Estevo
    Maisterra, Olga
    CEREBROVASCULAR DISEASES, 2014, 37 (03) : 181 - 187
  • [38] The selection of antithrombotic agents in the prevention of recurrent ischemic stroke
    Cathy M. Helgason
    Current Cardiology Reports, 2003, 5 (2) : 148 - 152
  • [39] Causes and Secondary Prevention of Acute Ischemic Stroke in Adults
    Jensen, Maerit
    Thomalla, Goetz
    HAMOSTASEOLOGIE, 2020, 40 (01): : 22 - 30
  • [40] New strategies for prevention of ischemic stroke: The LIFE study
    Harold P. Adams
    Current Neurology and Neuroscience Reports, 2003, 3 (1) : 46 - 51